Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: RBFOX2

Gene summary for RBFOX2

Gene summary.

Gene information	Species	Human
	Gene symbol	RBFOX2
	Gene ID	23543
	Gene name	RNA binding fox-1 homolog 2
	Gene Alias	FOX2
	Cytomap	22q12.3
	Gene Type	protein-coding
	GO ID	GO:0000375
	UniProtAcc	O43251

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
23543	RBFOX2	C04	Human	Oral cavity	OSCC	3.06e-07	6.58e-01	0.2633
23543	RBFOX2	C21	Human	Oral cavity	OSCC	4.81e-23	9.20e-01	0.2678
23543	RBFOX2	C30	Human	Oral cavity	OSCC	2.09e-26	1.24e+00	0.3055
23543	RBFOX2	C43	Human	Oral cavity	OSCC	1.63e-04	1.45e-01	0.1704
23543	RBFOX2	C51	Human	Oral cavity	OSCC	9.60e-11	7.47e-01	0.2674
23543	RBFOX2	C57	Human	Oral cavity	OSCC	5.00e-05	3.92e-01	0.1679
23543	RBFOX2	C06	Human	Oral cavity	OSCC	5.43e-10	1.47e+00	0.2699
23543	RBFOX2	C08	Human	Oral cavity	OSCC	2.54e-13	3.97e-01	0.1919
23543	RBFOX2	LP15	Human	Oral cavity	LP	7.98e-04	9.12e-01	0.2174
23543	RBFOX2	EOLP-1	Human	Oral cavity	EOLP	9.88e-03	1.84e-01	-0.0202
23543	RBFOX2	NEOLP-1	Human	Oral cavity	NEOLP	1.64e-15	4.86e-01	-0.0194
23543	RBFOX2	NEOLP-2	Human	Oral cavity	NEOLP	7.15e-14	4.18e-01	-0.0196
23543	RBFOX2	NEOLP-3	Human	Oral cavity	NEOLP	4.77e-13	3.87e-01	-0.0191
23543	RBFOX2	SYSMH1	Human	Oral cavity	OSCC	3.58e-05	1.13e-01	0.1127
23543	RBFOX2	SYSMH3	Human	Oral cavity	OSCC	5.59e-12	4.31e-01	0.2442
23543	RBFOX2	SYSMH4	Human	Oral cavity	OSCC	4.95e-03	-1.66e-01	0.1226
23543	RBFOX2	SYSMH5	Human	Oral cavity	OSCC	1.81e-03	5.09e-02	0.0647
23543	RBFOX2	HTA12-15-2	Human	Pancreas	PDAC	9.02e-12	7.77e-01	0.2315
23543	RBFOX2	HTA12-23-1	Human	Pancreas	PDAC	2.52e-12	1.08e+00	0.3405
23543	RBFOX2	HTA12-25-1	Human	Pancreas	PDAC	7.85e-10	7.81e-01	0.313

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:004348410	Cervix	CC	regulation of RNA splicing	42/2311	148/18723	1.25e-07	6.24e-06	42
GO:003009910	Cervix	CC	myeloid cell differentiation	83/2311	381/18723	1.31e-07	6.42e-06	83
GO:190370610	Cervix	CC	regulation of hemopoiesis	80/2311	367/18723	2.14e-07	9.55e-06	80
GO:000226210	Cervix	CC	myeloid cell homeostasis	43/2311	157/18723	2.66e-07	1.12e-05	43
GO:00163587	Cervix	CC	dendrite development	58/2311	243/18723	4.52e-07	1.76e-05	58
GO:003410110	Cervix	CC	erythrocyte homeostasis	37/2311	129/18723	5.16e-07	1.93e-05	37
GO:004854510	Cervix	CC	response to steroid hormone	74/2311	339/18723	5.71e-07	2.09e-05	74
GO:19033119	Cervix	CC	regulation of mRNA metabolic process	64/2311	288/18723	1.71e-06	5.64e-05	64
GO:00305229	Cervix	CC	intracellular receptor signaling pathway	60/2311	265/18723	1.89e-06	5.97e-05	60
GO:003021810	Cervix	CC	erythrocyte differentiation	34/2311	120/18723	2.00e-06	6.18e-05	34
GO:004887210	Cervix	CC	homeostasis of number of cells	61/2311	272/18723	2.17e-06	6.55e-05	61
GO:004563710	Cervix	CC	regulation of myeloid cell differentiation	48/2311	210/18723	1.49e-05	2.93e-04	48
GO:00456468	Cervix	CC	regulation of erythrocyte differentiation	17/2311	47/18723	2.38e-05	4.16e-04	17
GO:004802410	Cervix	CC	regulation of mRNA splicing, via spliceosome	28/2311	101/18723	2.41e-05	4.19e-04	28
GO:00506849	Cervix	CC	regulation of mRNA processing	33/2311	137/18723	1.06e-04	1.35e-03	33
GO:000838010	Cervix	CC	RNA splicing	76/2311	434/18723	9.79e-04	8.19e-03	76
GO:00713839	Cervix	CC	cellular response to steroid hormone stimulus	40/2311	204/18723	1.93e-03	1.42e-02	40
GO:00488135	Cervix	CC	dendrite morphogenesis	30/2311	146/18723	3.27e-03	2.13e-02	30
GO:00305188	Cervix	CC	intracellular steroid hormone receptor signaling pathway	25/2311	116/18723	3.59e-03	2.30e-02	25
GO:000037710	Cervix	CC	RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	55/2311	320/18723	6.71e-03	3.70e-02	55

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

TF	Cell Type	Tissue	Disease Stage	Target Gene	RSS	Regulon Activity
RBFOX2	NUER	Prostate	ADJ	PPP1R12B,CHD9,DHX8, etc.	0.00e+00
RBFOX2	BAS	Prostate	ADJ	PPP1R12B,CHD9,DHX8, etc.	0.00e+00
RBFOX2	BAS	Prostate	Tumor	PPP1R12B,CHD9,DHX8, etc.	8.56e-03
RBFOX2	NUER	Prostate	Tumor	PPP1R12B,CHD9,DHX8, etc.	7.36e-03

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

RBFOX2

SNV

Missense_Mutation

c.964A>G

p.Ser322Gly

p.S322G

O43251

protein_coding

tolerated_low_confidence(0.31)

benign(0.015)

TCGA-AN-A0AK-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RBFOX2

SNV

Missense_Mutation

novel

c.383N>C

p.Asn128Thr

p.N128T

O43251

protein_coding

tolerated(0.93)

benign(0.019)

TCGA-D8-A1XG-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

RBFOX2

SNV

Missense_Mutation

c.434N>T

p.Ser145Leu

p.S145L

O43251

protein_coding

deleterious(0.04)

benign(0.015)

TCGA-D8-A27G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RBFOX2

SNV

Missense_Mutation

novel

c.383N>C

p.Asn128Thr

p.N128T

O43251

protein_coding

tolerated(0.93)

benign(0.019)

TCGA-E9-A1RE-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Hormone Therapy

tamoxiphen

RBFOX2

insertion

Frame_Shift_Ins

novel

c.547_548insTTTAT

p.Arg183LeufsTer29

p.R183Lfs*29

O43251

protein_coding

TCGA-A8-A079-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

5-fluorouracil

RBFOX2

insertion

Nonsense_Mutation

novel

c.546_547insGCATTACGATGATAGGATTGCAGATTAT

p.Arg183AlafsTer4

p.R183Afs*4

O43251

protein_coding

TCGA-A8-A079-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

5-fluorouracil

RBFOX2

SNV

Missense_Mutation

c.1073G>A

p.Arg358Gln

p.R358Q

O43251

protein_coding

deleterious(0.02)

probably_damaging(0.996)

TCGA-C5-A1MH-01

Cervix

cervical & endocervical cancer

Female

>=65

III/IV

Chemotherapy

cisplatin

RBFOX2

SNV

Missense_Mutation

novel

c.511N>C

p.Ser171Arg

p.S171R

O43251

protein_coding

tolerated(0.3)

benign(0.147)

TCGA-5M-AAT6-01

Colorectum

colon adenocarcinoma

Female

<65

III/IV

Unknown

RBFOX2

SNV

Missense_Mutation

c.1018N>A

p.Ala340Thr

p.A340T

O43251

protein_coding

tolerated(0.06)

benign(0.154)

TCGA-AA-3877-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

RBFOX2

SNV

Missense_Mutation

novel

c.292N>T

p.Ile98Phe

p.I98F

O43251

protein_coding

tolerated_low_confidence(0.09)

possibly_damaging(0.791)

TCGA-AM-5820-01

Colorectum

colon adenocarcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1